Edition:
United Kingdom

Healthcare

GSK.L
AZN.L
SHP.L

BRIEF-Anavex presents 31-week efficacy data from Alzheimer's phase 2a study

* Anavex presents 31-week efficacy data from phase 2a study of ANAVEX 2-73 in alzheimer's patients at AAIC 2016

6:05pm BST

Scientists find potential new antibiotic, right under their noses

LONDON, July 27 Scientists in Germany have discovered a bacteria hiding out in peoples' noses that produces an antibiotic compound that can kill several dangerous pathogens, including the superbug MRSA.

6:00pm BST

BRIEF-Txcell as of June 30 cash and cash equivalents amounted to EUR 3.2 million

* As of June 30, 2016, cash and cash equivalents amounted to 3.2 million euros ($3.52 million) Source text for Eikon: Further company coverage: ($1 = 0.9101 euros) (Gdynia Newsroom)

5:57pm BST

BRIEF-I.Ceram H1 revenue 783,000 euros versus 731,000 euros year ago

* H1 revenue 783,000 euros ($860,360.40) versus 731,000 euros year ago Source text: http://bit.ly/2avQ4wZ Further company coverage: ($1 = 0.9101 euros) (Gdynia Newsroom:)

5:51pm BST

BRIEF-Vectura initiates legal proceedings against GSK in the U.S.

* Vectura initiates legal proceedings against GlaxoSmithKline Plc (GSK)

5:50pm BST
Healthcare
GlaxoSmithKline PLC 1,696.50p +1.77%
AstraZeneca PLC 4,690.00p +1.11%
Shire PLC 4,906.00p -0.02%

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.